Lymphangioleiomyomatosis, doxycycline, respiratory tract diseases
Conditions
Interventions
31 female LAM patients have received doxycycline orally (100mg/day) for 6 months. They underwent evaluations at basal month and 6th month through pulmonary function tests, six-minute walk test (6MWT),
drug
Sponsors
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Eligibility
Sex/Gender
Female
Age
17 Years to 90 Years
Inclusion criteria
Inclusion criteria: Patients with an established clinical-radiological or histopathological diagnosis of lymphangioleiomyomatosis
Exclusion criteria
Exclusion criteria: Patients submitted previously to lung transplant
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| - Variation of urinary and serum metalloproteinase (MMP) -2 and -9 levels, after doxycycline treatment, according to the levels at the time of protocol´s admission. - Variation of FEV1 (forced expiratory volume in the first second), obtained from the difference between FEV1 after 6 months with doxycycline and the basal FEV1. | — |
Secondary
| Measure | Time frame |
|---|---|
| - Lung volumes (total lung capacity and residual volume), carbon monoxide diffusion capacity and variables derivated from the six-minute walk test, such as distance walked and minimal oxyhemoglobine saturation before and after doxycycline. - Variation of the Dessaturation- Distance Index, obtained from the ratio between desaturation area and the walked distance during six-minute walk test, after doxycicline - Adverse events during the treatment with doxycicline | — |
Countries
Brazil
Contacts
Public ContactSUZANA PIMENTA
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo
Outcome results
None listed